Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

271 ARTÍCULOS , VIENDO DEL 91 AL 105

Progress on early diagnosing Alzheimer's disease

Chen Y, Al-Nusaif M, Li S, Tan X, Yang H, Cai H, Le W.

Front Med. 2024 Jun;18(3):446-464. doi: 10.1007/s11684-023-1047-1. Epub 2024 May 21.

Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease

Penny LK, Lofthouse R, Arastoo M, Porter A, Palliyil S, Harrington CR, Wischik CM.

Transl Neurodegener. 2024 May 21;13(1):25. doi: 10.1186/s40035-024-00417-w.

Predicting Driving Cessation Among Cognitively Normal Older Drivers: The Role of Alzheimer Disease Biomarkers and Clinical Assessments

Babulal GM, Chen L, Murphy SA, Carr DB, Morris JC.

Neurology. 2024 Jun 25;102(12):e209426. doi: 10.1212/WNL.0000000000209426. Epub 2024 Apr 15.

Predicting Driving Cessation in Alzheimer Disease: Performance Beats Biomarkers

Dubinsky RM, Stein AC.

Neurology. 2024 Jun 25;102(12):e209523. doi: 10.1212/WNL.0000000000209523. Epub 2024 Apr 15.

GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for Combating Alzheimer's Disease through its Supporting DPP4 Inhibitors: A Review

Abubakar M, Nama L, Ansari MA, Ansari MM, Bhardwaj S, Daksh R, Syamala KLV, Jamadade MS, Chhabra V, Kumar D, Kumar N.

Curr Top Med Chem. 2024;24(19):1635-1664. doi: 10.2174/0115680266293416240515075450.

[Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease]

Blennow K, Hansson O.

Lakartidningen. 2024 May 31;121:23150.

Association of Loneliness with Functional Connectivity MRI, Amyloid-β PET, and Tau PET Neuroimaging Markers of Vulnerability for Alzheimer's Disease

Zhao A, Balcer LJ, Himali JJ, O'Donnell A, Rahimpour Y, DeCarli C, Gonzales MM, Aparicio HJ, Ramos-Cejudo J, Kenney R, Beiser A, Seshadri S, Salinas J.

J Alzheimers Dis. 2024;99(4):1473-1484. doi: 10.3233/JAD-231425.

Proteomics profiling of extracellular vesicle for identification of potential biomarkers in Alzheimer's disease: A comprehensive review

Pei J, Palanisamy CP, Jayaraman S, Natarajan PM, Umapathy VR, Roy JR, Thalamati D, Ahalliya RM, Kanniappan GV, Mironescu M.

Ageing Res Rev. 2024 Aug;99:102359. doi: 10.1016/j.arr.2024.102359. Epub 2024 May 29.

The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer's disease

Sarazin M, Lagarde J, El Haddad I, de Souza LC, Bellier B, Potier MC, Bottlaender M, Dorothée G.

Nat Aging. 2024 Jun;4(6):761-770. doi: 10.1038/s43587-024-00630-2. Epub 2024 Jun 5.

Biomarkers and Target-Specific Small-Molecule Drugs in Alzheimer's Diagnostic and Therapeutic Research: From Amyloidosis to Tauopathy

Sheng L, Bhalla R.

Neurochem Res. 2024 Sep;49(9):2273-2302. doi: 10.1007/s11064-024-04178-w. Epub 2024 Jun 6.

Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem® for Mild Alzheimer's Disease

Taylor J, Jaros M, Chen C, Harrison J, Hilt D.

J Alzheimers Dis. 2024;100(1):139-150. doi: 10.3233/JAD-231456.

Employing Informatics Strategies in Alzheimer's Disease Research: A Review from Genetics, Multiomics, and Biomarkers to Clinical Outcomes

Bao J, Lee BN, Wen J, Kim M, Mu S, Yang S, Davatzikos C, Long Q, Ritchie MD, Shen L.

Annu Rev Biomed Data Sci. 2024 Aug;7(1):391-418. doi: 10.1146/annurev-biodatasci-102423-121021. Epub 2024 Jul 24.

Alzheimer disease blood biomarkers: considerations for population-level use

Mielke MM, Fowler NR.

Nat Rev Neurol. 2024 Aug;20(8):495-504. doi: 10.1038/s41582-024-00989-1. Epub 2024 Jun 11.

TWINGEN: protocol for an observational clinical biobank recall and biomarker cohort study to identify Finnish individuals with high risk of Alzheimer's disease

Vuoksimaa E, Saari TT, Aaltonen A, Aaltonen S, Herukka SK, Iso-Markku P, Kokkola T, Kyttälä A, Kärkkäinen S, Liedes H, Ollikainen M, Palviainen T, Ruotsalainen I, Toivola A, Urjansson M, Vasankari T, Vähä-Ypyä H, Forsberg MM, Hiltunen M, Jalanko A, Kälviäinen R, Kuopio T, Lähteenmäki J, Nyberg P, Männikkö M, Serpi R, Siltanen S, Palotie A, Kaprio J, Runz H, Julkunen V; FinnGen.

BMJ Open. 2024 Jun 12;14(6):e081947. doi: 10.1136/bmjopen-2023-081947.

Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease

Schindler SE, Galasko D, Pereira AC, Rabinovici GD, Salloway S, Suárez-Calvet M, Khachaturian AS, Mielke MM, Udeh-Momoh C, Weiss J, Batrla R, Bozeat S, Dwyer JR, Holzapfel D, Jones DR, Murray JF, Partrick KA, Scholler E, Vradenburg G, Young D, Algeciras-Schimnich A, Aubrecht J, Braunstein JB, Hendrix J, Hu YH, Mattke S, Monane M, Reilly D, Somers E, Teunissen CE, Shobin E, Vanderstichele H, Weiner MW, Wilson D, Hansson O.

Nat Rev Neurol. 2024 Jul;20(7):426-439. doi: 10.1038/s41582-024-00977-5. Epub 2024 Jun 12.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias